Literature DB >> 383261

Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer.

L R Zacharski, W G Henderson, F R Rickles, W B Forman, C J Cornell, R J Forcier, H W Harrower, R O Johnson.   

Abstract

Anticoagulants have been demonstrated to reduce tumor growth in certain experimental animal systems. Inhibition of clot formation interferes with tumor growth and spread while enhancement of coagulation promotes tumor growth and spread. The fact that the coagulation mechanism is commonly activated in human malignancy together with preliminary reports of therapeutic efficacy of anticoagulants suggests that the coagulation mechanism may be of pathophysiologic significance also in the growth of human tumors. A VA Cooperative Study has been established to test the hypothesis that warfarin anticoagulation will modify the course of malignancy in man. The purpose of this paper is to present the rationale and experimental design for this study with emphasis on management of anticoagulant administration in cancer patients. This paper serves as the basis for forthcoming reports of toxicity and therapeutic efficacy of warfarin in human malignancy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 383261     DOI: 10.1002/1097-0142(197908)44:2<732::aid-cncr2820440246>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Abnormal haemostasis in small cell lung cancer.

Authors:  R Milroy; J T Douglas; J Campbell; R Carter; G D Lowe; S W Banham
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

2.  Involvement of a cathepsin B-like cysteine proteinase in platelet aggregation induced by tumor cells and their shed membrane vesicles.

Authors:  P G Cavanaugh; B F Sloane; A S Bajkowski; G J Gasic; T B Gasic; K V Honn
Journal:  Clin Exp Metastasis       Date:  1983 Oct-Dec       Impact factor: 5.150

Review 3.  Post-translational carboxylation of preprothrombin.

Authors:  B C Johnson
Journal:  Mol Cell Biochem       Date:  1981-08-11       Impact factor: 3.396

4.  Fibrin deposits in Hodgkin's disease.

Authors:  N L Harris; A M Dvorak; J Smith; H F Dvorak
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

5.  Anticoagulant treatment of rats with Walker 256 carcinosarcoma.

Authors:  C A Owen
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

Review 6.  Fibrin as a component of the tumor stroma: origins and biological significance.

Authors:  H F Dvorak; D R Senger; A M Dvorak
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system.

Authors:  K V Honn
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

Review 8.  Clinical trials with anticoagulant and antiplatelet therapies.

Authors:  L R Zacharski; K R Meehan; S M Algarra; F A Calvo
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 9.  The role of fibrin in tumor metastasis.

Authors:  V Costantini; L R Zacharski
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 10.  Theories on the metastatic process and possible therapeutic options.

Authors:  P J Effert; T G Strohmeyer
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.